PMID: 25749041Mar 10, 2015Paper

Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia

Oncotarget
Jian-Yong LiSi-Xuan Qian

Abstract

This prospective phase II, open label, study was designed to assess the efficacy and safety of D-CAG induction treatment for elderly patients with newly diagnosed AML. All patients in this study were treated with decitabine of 15 mg/m2 for 5 days and G-CSF for priming, in combination with cytarabine of 10-mg/m2 q12h for 7 days and aclarubicin of 10 mg/day for 4 days (D-CAG). Among 85 evaluable patients, overall response rate (ORR) and complete remission (CR) were 82.4% and 64.7%, respectively, after 1 cycle of therapy. The ORR in patients aged <70 years was 83.0% and 81.6% in patients aged ≥70 years. There was a significantly longer median overall survival (OS) in patients with response (16 months) than in those without response (7 months, p< 0.0001). The OS for patients aged ≥70 years and 60-69 years was 10 months and 12 months, respectively (p=0.4994). The two-year OS probability was 19.2% and the twenty-month survival rate was 33.8%. Induction mortality of D-CAG treated elderly patients with AML is 4.4%. D-CAG regimen was well tolerated and showed a promising clinic efficacy in elderly patients with AML (≥70 years).

References

Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
May 19, 2006·Cancer Research·Allen S YangJean-Pierre J Issa
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elihu Estey
Jul 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Taichun QinJean-Pierre J Issa
Mar 18, 2008·Best Practice & Research. Clinical Haematology·Elihu H Estey
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lanlan ShenJean-Pierre J Issa

❮ Previous
Next ❯

Citations

Nov 22, 2015·Science China. Life Sciences·AiLi ChenQian-Fei Wang
Oct 28, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lei GaoXi Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.